Table 1 Summary of the cases in which... | American Society of Hematology

Table 1

Summary of the cases in which BCR-ABL KD mutation analysis is recommended

At diagnosis

Only in AP/BC patients

During first-line imatinib therapy

In case of failure

In case of an increase in BCR-ABL transcript levels leading to MMR loss

In any other case of suboptimal response

During second-line dasatinib or nilotinib therapy

In case of hematologic or cytogenetic failure

AP indicates accelerated phase.